Patents Assigned to Gensia, Inc.
-
Patent number: 5775329Abstract: The present invention relates generally to methods of diagnosis, evaluation and treatment of coronary artery disease in mammals using substituted catecholamines and compounds therefore. It also relates to the preparation, use and administration of these compounds which are useful in the diagnosis, evaluation and treatment of coronary artery disease by means of a feedback controlled drug delivery system that delivers exercise simulating agents which are capable of eliciting acute responses similar to those elicited by aerobic exercise.Type: GrantFiled: June 7, 1995Date of Patent: July 7, 1998Assignee: Gensia, Inc.Inventors: Ernest K. Metzner, Mark D. Erion
-
Patent number: 5777100Abstract: Analogs of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide (AICA riboside) are provided which are useful in increasing extracellular levels of adenosine.Type: GrantFiled: June 7, 1995Date of Patent: July 7, 1998Assignee: Gensia Inc.Inventors: David A. Bullough, Harry E. Gruber, Ernest K. Metzker, Kevin M. Mullane, Bheemarao G. Ugarkar, Clinton E. Browne
-
Patent number: 5726302Abstract: This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to water soluble, aryl substituted 4-amino pyrrolo?2,3-d! pyrimidine and pyrazolo?3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.Type: GrantFiled: June 7, 1995Date of Patent: March 10, 1998Assignee: Gensia Inc.Inventors: Bheemarao G. Ugarkar, Mark D. Erion, Jorge E. Gomez Galeno
-
Patent number: 5721356Abstract: This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to orally active, substituted 5-aryl pyrrolo?2,3-d!pyrimidine and 3-aryl pyrazolo?3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.Type: GrantFiled: June 7, 1995Date of Patent: February 24, 1998Assignee: Gensia, Inc.Inventors: Bheemarao G. Ugarkar, Mark D. Erion, Jorge E. Gomez Galeno, Angelo J. Castellino, Clinton E. Browne
-
Patent number: 5674998Abstract: This invention relates to adenosine kinase inhibitors and to nucleoside analogs, C-4' modified pyrrolo?2,3-d!pyrimidine and pyrazolo?3,4-d!pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention relates to nucleoside analogs of this kind, having zero substitutions or two substitutions at the C-4' position of the furanose (sugar) moiety. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.Type: GrantFiled: June 7, 1995Date of Patent: October 7, 1997Assignee: Gensia Inc.Inventors: Serge H. Boyer, Mark D. Erion, Bheemarao G. Ugarkar
-
Patent number: 5646128Abstract: Novel compounds which selectively inhibit adenosine kinase and methods of preparing adenosine kinase inhibitors are provided. Also provided are methods of treating various inflammatory conditions, including arthritis and SIRS, which may be ameliorated by increased local concentrations of adenosine using adenosine kinase inhibitors.Type: GrantFiled: December 1, 1994Date of Patent: July 8, 1997Assignee: Gensia, Inc.Inventors: Gary S. Firestein, Bheemarao G. Ugarkar, Leonard P. Miller, Harry E. Gruber, David A. Bullough, Mark D. Erion, Angelo J. Castellino, Clinton E. Browne
-
Patent number: 5573772Abstract: Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptor.Type: GrantFiled: March 17, 1994Date of Patent: November 12, 1996Assignees: Gensia, Inc., South Alabama Medical Science FoundationInventors: James M. Downey, Kevin M. Mullane
-
Patent number: 5506347Abstract: Novel lyxose derivatives which selectively inhibit adenosine kinase and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions in vivo which may be ameliorated by increased local concentrations of adenosine.Type: GrantFiled: February 3, 1994Date of Patent: April 9, 1996Assignee: Gensia, Inc.Inventors: Mark D. Erion, Bheemarao G. Ugarkar, Angelo J. Castellino
-
Patent number: 5460605Abstract: Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.Type: GrantFiled: December 7, 1993Date of Patent: October 24, 1995Assignee: Gensia, Inc.Inventors: Ronald R. Tuttle, Clinton E. Browne
-
Patent number: 5443836Abstract: Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptors.Type: GrantFiled: March 15, 1993Date of Patent: August 22, 1995Assignees: Gensia, Inc., South Alabama Medical Science FoundationInventors: James M. Downey, Kevin Mullane
-
Patent number: 5383848Abstract: Methods, formulations, and a system for improved iontophoretic administration of a drug, by, preferably, topical administration of a formulation containing an active vasodilator, rubefacient, or counterirritant agent such as capsaicin on the skin at the electrode site, or, iontophoretic administration of a vasodilator formulation or alpha blocker prior to iontophoretic administration of the drug.Type: GrantFiled: April 4, 1991Date of Patent: January 24, 1995Assignee: Gensia, Inc.Inventors: Robert S. Hillman, John M. Pawelchak